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ABSTRACT
Background. Borderline personality disorder (BPD) is often co-morbid with major depression and
may complicate its treatment. We were interested in diﬀerences in genetic and developmental risk
factors between depressed patients with or without a co-morbid BPD.
Method. Out-patients with major depressive disorder were recruited for two treatment trials.
Assessment of depressed patients included the assessment of personality disorders, developmental
risk factors and DNA samples for genetic analyses.
Results. In each study there was a signiﬁcant association between the 9-repeat allele of the dopa-
mine transporter (DAT1) and BPD, with odds ratios (OR) >3 and pf0.02. This association re-
mained signiﬁcant when developmental risk factors for BPD (childhood abuse and neglect and
borderline temperament) were also included in the analyses. The OR was even larger in the
depressed patients agedo35 years (OR 9.31, p=0.005).
Conclusion. This replicated association in depressed patients between the 9-repeat allele of DAT1
and BPD may provide clues to understanding the neurobiology of BPD. The ﬁnding that
the association is larger in the older depressed patients, suggests that the 9-repeat allele may be
associated with a poorer prognosis BPD, rather than a young adult limited variant of BPD.
INTRODUCTION
Borderline personality disorder (BPD) is a
severe disorder of personality characterized by a
pervasive and pathological pattern of aﬀective
instability, intense and unstable close relation-
ships, instability of self-image, feelings of aban-
donment and boredom, and a range of impulsive
behaviours including repeated suicide attempts
and self-mutilation. Due to the intensity of
emotions and the range of impulsive behav-
iours, patients with the disorder are often seen
as among the most challenging to treat. In most
instances, BPD is usually co-morbid with other
mental disorders, especially mood and anxiety
disorders and substance abuse (Hyman, 2002;
Skodol et al. 2002a). There is no satisfactory
neurobiological model of BPD, but there are
suggestions that abnormalities of impulsive
aggression reﬂect abnormalities of reduced
serotonergic function, that aﬀective instability
may reﬂect increased responsivity of cholinergic
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systems (Skodol et al. 2002b), although there
are grounds for implicating dopamine dys-
function in emotional dysregulation, impulsivity
and cognitive-perceptual impairment (Friedel,
2004). Furthermore, traits such as high novelty-
seeking which are associated with BPD may re-
ﬂect altered dopaminergic function (Cloninger,
2000). The high co-morbidity of BPD with sub-
stance abuse also suggests that abnormalities of
dopaminergic reward pathways could be im-
plicated in both disorders (Ebstein et al. 2000).
The dopamine transporter gene SLC6A3
(DAT1) contains 15 exons, is localized to chrom-
osome 5p15.3 and is a member of the large
Na+/Clx dependent family of transporters
(Vandenbergh et al. 1992; Giros et al. 1996).
DAT1 functions to rapidly re-uptake dopamine
from the synaptic cleft into the pre-synaptic
terminals and thus acts as a key component in
regulating dopaminergic neurotransmission
(Kelsoe et al. 1996). Inactivation of the DAT1
gene in mice led to a prolonged persistence of
dopamine in the extracellular space (Giros et al.
1996).
Genetic variation in SLC6A3 may aﬀect the
expression of DAT1, impacting on the func-
tioning of CNS dopaminergic systems. A 40-bp
polymorphic variable number tandem repeats
(VNTR) is present in the 3k untranslated
region of the gene and can vary from 3 to 12
repeatsDoucette-Stamm et al. 1995; Gelernter
et al. 1998). Genetic association studies have
inconsistently linked the 9-repeat allele to at-
tention deﬁcit hyperactivity disorder (ADHD)
(Cook et al. 1995; Gill et al. 1997; Daly et al.
1999; Madras et al. 2005), the severity of al-
cohol withdrawal in alcohol-dependent sub-
jects (Sander et al. 1997; Schmidt et al. 1998;
Heinz et al. 2004), and to prolonged psychosis
following stimulant withdrawal (Ujike et al.
2003). There is currently no consensus on how
the 9- and 10-repeat alleles may aﬀect the ex-
pression of SLC6A3. Due to the untranslated
nature of the VNTR it cannot aﬀect the
structure and function of DAT1, but may be
involved in the regulation of the gene (Bannon
et al. 2001; Mill et al. 2002).
In a ﬁrst-depression treatment study (Joyce
et al. 2002) in which we had particular interests
in the impact of personality and personality
disorders on treatment outcome (Joyce et al.
2003a, 2004; Mulder et al. 2003), and while
undertaking analyses on the association be-
tween genetic polymorphisms and personality
(Sullivan et al. 1997; Joyce et al. 2003b ; Roberts
et al. 2004), we observed a signiﬁcant relation-
ship between the 9-repeat allele of DAT1 and
BPD. As this association was found in explora-
tory analyses and as we were undertaking
another depression treatment study, we at-
tempted to replicate the initial ﬁnding. We also
decided to explore how other risk factors for
BPD, such as childhood abuse and neglect and
temperament inﬂuenced any possible associ-
ation of DAT1 with BDP.
METHOD AND SUBJECTS
Subjects and assessment
For both out-patient depression treatment stud-
ies we recruited patients, aged o18 years, with
a principal current diagnosis of major de-
pression. Exclusion criteria were minimized but
included a history of schizophrenia or mania (a
history of hypomania was allowed), a principal
current diagnosis of severe alcohol or drug de-
pendence, or severe current medical illness. In
addition, patients needed to be free of psycho-
tropic medication for a minimum of 2 weeks, or
ﬁve drug half-lives, except for an occasional
hypnotic for sleep. Patients also could not have
received in the past 12 months an adequate
treatment trial of one of the trial treatments to
which they could be randomized. In the ﬁrst
depression treatment trial, patientswere random-
ized to ﬂuoxetine or nortriptyline (Joyce
et al. 2002) ; and in the second trial they were
randomized to interpersonal psychotherapy or
cognitive behaviour therapy (Joyce et al. un-
published observations ; Luty et al. unpublished
observations). The two trials ran sequentially, in
the same university-based out-patient Clinical
Research Unit, and were the only depression
treatment studies being undertaken in the
Department at the time. Both treatment studies
had been approved by the Canterbury (New
Zealand) Ethics Committee. After expla-
nation of the studies all patients provided
written informed consent.
Assessment included the Structured Clinical
Interview for DSM (SCID; Spitzer et al. 1992),
which had been expanded to include assessment
of all DSM-III-R and DSM-IV melancholic and
atypical depression symptoms. Approximately
808 P. R. Joyce et al.
6 weeks after commencing treatment a trained
psychiatrist or clinical psychologist completed
the Structured Clinical Interview for Axis II
Personality Disorders (SCID-II; Spitzer et al.
1987).
During the baseline assessment patients com-
pleted a series of self-report questionnaires, in-
cluding the Parental Bonding Instrument (PBI;
Parker et al. 1979) and the Temperament and
Character Inventory (TCI; Svrakic et al. 1993).
Patients were also interviewed by a research
nurse who systematically enquired about child-
hood (prior to 16 years) physical, emotional
and sexual abuse. DNA was also collected for
genetic studies.
Genotyping
Our method for DAT1 genotyping was based on
the polymerase chain reaction method of
Vandenbergh et al. (1992) but with modiﬁ-
cations as previously described (Sullivan et al.
1997).
Data analysis
All data were entered into a relational database
and later transferred to the statistical package
SYSTAT for statistical analysis (Systat Inc., 1990).
The principal statistical approach was logistic
regression. When the association of multiple
risk variables with BPD was being analysed,
multiple logistic regression was used. In the
multiple logistic regression analyses we also
examined for generenvironment interaction
eﬀects.
For the purposes of this study, childhood
neglect was calculated by averaging the ma-
ternal and paternal care scales of the PBI. Scores
were then divided into quartiles, so that the
absence of childhood neglect (score of zero)
indicated that a patient reported maternal and
paternal care scores in the top quartile. A rating
of severe neglect (score of 3) indicated that a
patient had reported maternal and paternal care
scores in the bottom quartile.
The childhood abuse score was based upon
the assessment of both the type and frequency of
childhood abuse experiences. A score of zero
means that an individual reported no childhood
abuse experiences. A score of 3 (severe abuse)
represents repeated childhood physical and/or
sexual abuse. Scores of 1 or 2 indicate either
lesser severity (e.g. sexual touching, but not
intercourse) and/or lesser frequency (e.g. one
episode of sexual abuse).
The combined childhood abuse plus neglect
variable was determined by adding the child-
hood abuse plus the childhood neglect scores
(possible totals were 0–6). The combined vari-
able was assigned a score of zero when the cal-
culated score was zero; the combined variable
was assigned a score of 1 when the calculated
score was 1 or 2; the combined variable was
assigned a score of 2 when the calculated score
was 3–5; and the combined variable was as-
signed a score of 3 when the calculated score was
6. Thus, a childhood abuse plus neglect score of
zero implies the patient reported no childhood
abuse experiences and rated their parents in the
top quartile for care and warmth. A score of 3
implies the patient was in the bottom quartile
for care and warmth and reported severe re-
peated childhood abuse.
Borderline temperament was a quartile score
based on the novelty-seeking score multiplied by
the harm-avoidance score (reﬂecting approach-
avoidance conﬂict). The two temperament
measures were assessed by self-report on the
TCI at the time of entry into the studies.
RESULTS
Table 1 shows the allele and gene frequency for
DAT1, the prevalence of BPD and the associ-
ation of a 9-repeat polymorphism with BPD in
each of the two samples. While the association
[odds ratio (OR) 3.07, p=0.018] in the ﬁrst
sample was found while undertaking explora-
tory analyses and, therefore, could be ascribed
to chance, the association is remarkably similar
in the second independent sample (OR 3.15,
p=0.020). If both studies are combined the OR
remains>3 but the p value is<0.001.
Other recognized risk factors for BPD include
childhood abuse and neglect (Zanarini et al.
1997), a borderline temperament (Svrakic et al.
1993; Joyce et al. 2003a), and a younger age
(Zanarini et al. 2003). Table 2, in which the
separate samples have been combined, shows
the signiﬁcant univariate associations of BPD
with age, DAT1 polymorphism, childhood
neglect, childhood abuse, a combined variable
called childhood abuse and neglect, and bor-
derline temperament.
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As the combined variable of childhood abuse
plus neglect was the strongest predictor of
BPD in univariate analyses, this variable along
with borderline temperament, age and the 9-
repeat allele of DAT were entered into a mul-
tiple logistic regression. Table 3 shows that the
adjusted OR for the 9-repeat allele was 3.10
(p=0.002), and that childhood abuse plus
neglect and borderline temperament and age
were all signiﬁcant independent predictors for
the presence of BPD. No signiﬁcant interaction
terms were found.
To demonstrate the eﬀects of the three major
risk factors on the prevalence of BPD in the
combined depressed sample, the childhood
abuse plus neglect and borderline temperament
variables were collapsed into dichotomized
variables. Fig. 1 shows that the likelihood of
BPD is increased by the presence of the 9-repeat
allele across all combinations of temperamental
and childhood risk factors.
As BPD often remits with age, often during
the fourth decade (Zanarini et al. 2003), we
examined the association of the 9-repeat poly-
morphism with BPD as a function of age. In
those aged <35 years the adjusted OR for the
9-repeat allele was only 2.03 (p=0.098), while
childhood abuse plus neglect remained the
strongest risk factor. However, in those aged
o35 years the adjusted OR for the 9-repeat
allele increased to 9.18 (p=0.007) and was the
strongest risk factor. The adjusted OR of>9 in
the older depressed patients was also consistent
across samples.
Across samples only 21 (6.2%) were homo-
zygous for the 9-repeat allele, and of these
23.8% had BPD; in those with just one copy of
the 9-repeat allele the prevalence of BPD was
similar at 19.7%. Both these rates of BPD are
Table 3. Results from a multiple logistic re-
gression predicting BPD from a combination of
risk factors
Adjusted OR 95% CI p
9-repeat allele 3.10 (1.51–6.35) 0.002
Childhood abuse plus neglect 2.64 (1.62–4.29) <0.001
Borderline temperament 1.66 (1.14–1.07) 0.008
Age group 0.49 (0.22–1.07) 0.074
BPD, Borderline personality disorder ; OR, odds ratio; CI, conﬁ-
dence interval.
Table 1. The frequency of dopamine transporter
polymorphisms, the prevalence of BPD, and the
association (odds ratio) of a 9-repeat polymorph-
ism with BPD in two independent depressed
samples
Sample 1 Sample 2
n 157 178
Age (yr) 32.3 (¡11.6) 35.5 (¡10.1)
% Female 57.0 70.0
DAT1 allele frequency
% 9-repeat 22.6 24.7
% 10-repeat 76.4 74.7
% 11- or 12-repeat 1.0 0.6
DAT1 genotype frequency
9-repeat homozygote 5.1% 7.3%
9-repeat heterozygote 35.0% 34.8%
No 9-repeat allele 59.9% 57.9%
% BPD 14.0 11.8




BPD, Borderline personality disorder ; OR, odds ratio; CI,
conﬁdence interval.
Table 2. Univariate associations of age, dopa-
mine transporter polymorphism, childhood ex-
periences and borderline temperament with BPD
in the combined depressed samples
n % BPD OR (95% CI) p
Age group
<35 years 182 16.5 0.47 (0.24–0.94) 0.032
o35 years 153 8.5
Dopamine transporter
9-repeat absent 197 7.6 3.09 (1.58–6.04) 0.001
9-repeat present 138 20.3
Childhood neglect









Childhood abuse plus neglect





Very low 74 2.7 1.84 (1.31–2.57) <0.001
Low 90 7.8
High 91 16.5
Very high 79 21.5
BPD, Borderline personality disorder ; OR, odds ratio; CI,
conﬁdence interval.
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higher than the 7.6% in those without a 9-
repeat allele. In both samples more than 95%
are caucasians. For residents of Christchurch,
New Zealand the vast majority of ancestors
came from the United Kingdom. Excluding the
few non-caucasians from the sample does not
alter the ﬁndings.
DISCUSSION
In this paper we have presented a replicated
association between the presence of a 9-repeat
allele of DAT1 and BPD in two independently
recruited depressed out-patient samples. We
have also shown that this association remains
signiﬁcant when other potential developmental
risk factors for BPD, such as childhood abuse
plus neglect and borderline temperament, and
age are included in multiple logistic regression.
Furthermore, the association is stronger in the
older depressed patients, when BPD is less
common. This last ﬁnding raises the possibility
that the 9-repeat allele is associated with a
more persistent BPD, rather than a young adult
limited variant.
A persistent diﬃculty in psychiatric genetics
has been in the meaning of replication. In our
view, it is compelling that we found essentially
identical ORs and conﬁdence intervals in two in-
dependent clinical samples. From a probabilistic
perspective, a signiﬁcant ﬁnding in only one
sample may well be a false positive; signiﬁcant
ﬁndings in two consecutive samples decrease
the probability of a false positive considerably.
Critically, the magnitude of this decrease de-
pends on the prior probability of association
before the second sample was analysed. Using
the approach described by Wacholder et al.
(2004), the cut-oﬀ for the noteworthiness of the
association in our second sample is a prior
probability of y0.04. In other words, if the
combination of the accumulated literature of
the importance of DAT1*9 plus the empirical
ﬁnding in our ﬁrst sample increased the prior
probability to po0.04, then the second sample
ﬁnding would have a false-positive report
probability of under 50% (i.e. ‘ the preponder-
ance of evidence ’). Therefore, taken together,
our ﬁndings suggest (but certainly do not prove)
the importance of the association of DAT1*9
and BPD.
One potential limitation of these ﬁndings is
that the association has been found in clinical
samples of depressed patients. In the com-
munity, the prevalence of BPD is about 1–2%,
but in out-patient samples it is often 10–15%
(Hyman, 2002). Mood disorders increase the
risk of BPD. Any depression sample is thus an
‘enriched’ sample, and it is possible that our
ﬁndings in two depressed samples, may not ex-
tend to the minority of BPD patients who do
not suﬀer from depression. It is also of note,
that while the population prevalence of BPD is
only 1–2%, approximately 40% of the popu-
lation have a 9-repeat DAT1 allele. Even in our
‘enriched’ depression samples the prevalence of
BPD in those with a 9-repeat allele is only 2.9%
in the absence of measured developmental risk
factors. It could perhaps be argued that the ab-
sence of the 9-repeat allele is protective against
the development of BPD when there are other
developmental risk factors.
The ﬁnding that the 9-repeat allele of DAT1 is
a risk factor for BPD supports a dopamine
dysfunction hypothesis of borderline person-
ality disorder (Friedel, 2004). Such a possibility






















FIG. 1. The probability of borderline personality disorder (BPD) in
relationship to diﬀerent combinations of the dopamine transporter
polymorphism, childhood abuse plus neglect and borderline
temperament.%, 9-repeat absent;&, 9-repeat present.
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to have brief psychotic episodes when under
stress, and the possible role of antipsychotic
drugs in the management of some BPD patients
(Oldham et al. 2001). Animal research suggests
that repeated exposure to social stress has long-
term eﬀects on dopamine transporter density
(Lucas et al. 2004) and that DAT1 knock-out
mice demonstrate abnormalities of social inter-
action secondary to a behavioural inﬂexibility
(Rodriguiz et al. 2004). These animal ﬁndings
involving behavioural eﬀects related to DAT1,
plus our ﬁnding that a polymorphism of DAT1
is a risk factor, suggest new avenues for research
into the neurobiology of BPD.
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